, its natural active ligand, by directly regulating the calcium ion channel (TRPV6) and degradation enzyme (CYP24A1), and indirectly regulating the parathyroid hormone (PTH) for feedback regulation of the synthetic enzyme CYP27B1. Studies that examined the intricate relationships between plasma and tissue 1,25(OH) 2D3 levels and changes in VDR target genes and plasma calcium and PTH are virtually nonexistent. In this study, we investigated temporal correlations between tissue 1,25(OH) 2D3 concentrations and VDR target genes in ileum and kidney and plasma calcium and PTH concentrations in response to 1,25(OH) 2D3 treatment in mice (2.5 g/kg ip, singly or q2d ϫ 4). After a single ip dose, plasma 1,25(OH) 2D3 peaked at ϳ0.5 h and then decayed biexponentially, falling below basal levels after 24 h and then returning to baseline after 8 days. Upon repetitive ip dosing, plasma, ileal, renal, and bone 1,25(OH) 2D3 concentrations rose and decayed in unison. Temporal profiles showed increased expressions of ileal Cyp24a1 and renal Cyp24a1, Mdr1/P-gp, and VDR but decreased renal Cyp27b1 mRNA after a time delay in VDR activation. Increased plasma calcium and attenuated PTH levels and increased ileal and renal Trpv6 expression paralleled the changes in tissue 1,25(OH) 2D3 concentrations. Gene changes in the kidney were more sustained than those in intestine, but the magnitudes of change for Cyp24a1 and Trpv6 were lower than those in intestine. The data revealed that 1,25(OH) 2D3 equilibrates with tissues rapidly, and VDR target genes respond quickly to exogenously administered 1,25(OH) 2D3. Upon binding of 1,25(OH) 2 D 3 to VDR, the complex undergoes a conformational change and translocates to the nucleus to heterodimerize with the retinoid X receptor (RXR) (4, 32), followed by recruitment of coactivators before binding to vitamin D response elements (VDREs) in promoter regions of VDR-responsive genes to initiate gene transcription (19). One of the physiological roles of 1,25(OH) 2 D 3 is to increase plasma calcium levels through transactivation of the calcium ion channels [transient receptor potential cation channel subfamily V members 5 and 6 (TRPV5 and TRPV6)] in the kidney and intestine (46). It is known that calcium is maintained by the concerted actions in not only the epithelia of the kidney and intestine, but also bone, where turnover is a continuous process involving both resorption of existing bone and deposition of new bone, processes that are stimulated by actions of 1,25(OH) 2 D 3 and the parathyroid hormone, PTH (28, 30).
1␣,25-DIHYDROXYVITAMIN D 3 [1, 25(OH) 2 D 3 ] is the active form of vitamin D and natural ligand of the vitamin D receptor (VDR), a member of the steroid/thyroid hormone nuclear receptor superfamily (34) . Vitamin D is formed from 7-dehydrocholesterol in skin upon exposure to the ultraviolet rays of the sun (270 -300 nm) and is hydroxylated by the cytochrome P-450s (CYP2R1 and CYP27A1) in liver to form 25-hydroxyvitamin D 3 [25(OH)D 3 ] . This inactive metabolite is transported by the vitamin D binding protein (DBP) and taken up by the endocytic receptor megalin into renal proximal tubular cells (41, 48) for activation by the 1␣-hydroxylase (CYP27B1) to form the active metabolite, 1,25(OH) 2 D 3 (30, 49) .
Upon binding of 1,25(OH) 2 D 3 to VDR, the complex undergoes a conformational change and translocates to the nucleus to heterodimerize with the retinoid X receptor (RXR) (4, 32) , followed by recruitment of coactivators before binding to vitamin D response elements (VDREs) in promoter regions of VDR-responsive genes to initiate gene transcription (19) . One of the physiological roles of 1,25(OH) 2 D 3 is to increase plasma calcium levels through transactivation of the calcium ion channels [transient receptor potential cation channel subfamily V members 5 and 6 (TRPV5 and TRPV6)] in the kidney and intestine (46) . It is known that calcium is maintained by the concerted actions in not only the epithelia of the kidney and intestine, but also bone, where turnover is a continuous process involving both resorption of existing bone and deposition of new bone, processes that are stimulated by actions of 1,25(OH) 2 D 3 and the parathyroid hormone, PTH (28, 30) .
The level of 1,25(OH) 2 D 3 in plasma is tightly controlled by two major cytochrome enzymes in the kidney, CYP27B1 or 1␣-hydroxylase, which converts 25(OH)D 3 to 1,25(OH) 2 (23) . CYP24A1 is present in tissues that express VDR (3) and serves as a biomarker for VDR activation. When 1,25(OH) 2 D 3 in plasma is high, CYP24A1 becomes highly induced in the kidney to increase catabolism (36) . When the circulating calcium concentration is low, the parathyroid gland responds by stimulating the production of PTH to downregulate CYP24A1 mRNA stability in kidney, reducing 1,25(OH) 2 D 3 degradation to result in higher plasma levels of 1,25(OH) 2 D 3 (56, 57) . When plasma calcium level is high, activation of the calcium-sensing receptor (CaSR) leads to reduction of PTH (23, 30) . In the intestine, the CYP24A1 level is regulated by 1,25(OH) 2 D 3 and not PTH (45) , suggesting that induction of CYP24A1 in the intestine is more of an acute response to VDR than the kidney (26) .
Within the past decade, the VDR has been implicated to play an important role in the regulation of drug enzymes and transporters. VDR-responsive drug-metabolizing enzymes include the cytochrome P-450s [human CYP3A4, CYP2B6, and CYP2C9 (17, 50) , and rodent Cyp3a1, Cyp3a9, and Cyp24a1 (12, 14) ] and sulfotransferase-2A1 (SULT2A1) (20) . VDRresponsive transporters include the rat apical sodium-dependent bile acid transporter (Asbt) (10) , human organic aniontransporting polypeptide (OATP1A2) (21) , multidrug resistance protein-1 or P-glycoprotein (MDR1/P-gp) (44) , and the human and rodent multidrug resistance-associated proteins (MRP2/Mrp2, Mrp3, MRP4/Mrp4) both in vitro and in vivo (14, 22) . Our laboratory has shown that VDR transactivates P-gp in brain microvessel endothelia (18) in vitro and P-gp in murine kidney and brain but not ileum and liver in vivo, leading to hastened efflux of digoxin in the brain and kidney (11) .
Clinically, the concentration of 25(OH)D 3 in plasma (nM range) is used as the biomarker for vitamin D status, although this value does not reflect the concentration of its active metabolite, 1,25(OH) 2 D 3 (pM range) formed via CYP27B1, the rate-limiting enzyme (19, 53) . Thus, there is the need to define precisely the pharmacological effects and interplay between 1,25(OH) 2 D 3 and the respective VDR target genes. A temporal study was thus undertaken to examine tissue levels of 1,25(OH) 2 D 3 on changes in VDR target genes in mice in a time-dependent manner after repeated administration of small doses of 1,25(OH) 2 D 3 (2.5 g/kg ip q2d ϫ 4). We aimed to test the hypotheses that 1,25(OH) 2 D 3 enters and equilibrates with tissues readily and that effects of VDR-responsive genes are delayed after entry of 1,25(OH) 2 D 3 in the tissue, since signal transduction is a multistep process involving multiple organs and feedback mechanisms.
METHODS
Materials. 1,25(OH)2D3 in powder form was purchased from Sigma-Aldrich Canada (Mississauga, ON, Canada). Antibodies to Cyp24 (H-87) and villin (C-19) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), anti-Gapdh (cat. no. ab8245) and anti-Trpv6 (cat. no. ab63084) from Abcam (Cambridge, MA), and P-gp from ID Labs (London, ON, Canada). All other reagents were purchased from Sigma-Aldrich Canada (Mississauga, ON, Canada) and Fisher Scientific (Mississauga, ON, Canada). The enzyme immunoassay (EIA) kit (cat. no. AC-62F1) for 1,25(OH) 2D3 measurement was manufactured by Immunodiagnostics Systems (IDS; Scottsdale, AZ) and purchased from Inter Medico (Markham, ON, Canada). The mouse PTH 1-84 ELISA kit, manufactured by Immutopics International (San Clemente, CA), was obtained via Joldon Diagnostics (Burlington, ON, Canada).
Pharmacokinetic study of 1, 25(OH) 2D3 in mice. Anhydrous ethanol was used to dissolve the 1,25(OH)2D3 powder, and the resulting concentration was measured spectrophotometrically at 265 nm (UV-1700, Shimadzu Scientific Instruments) before dilution with sterile corn oil. For in vivo pharmacokinetic studies in male, C57BL/6 mice (8 wk old), doses of either 0 or 2.5 g/kg (or 0.05 g/mouse or 120 pmol) 1,25(OH) 2D3, dissolved in sterile corn oil (5 l/g), were given ip on days 0, 2, 4, and 8 at 9 AM. The dose was based on a series of published reports, with doses ranging from 0.1 to 5 g/mouse or 0.25 to 5 g/kg for ip or oral administration, daily or every other day in mice (1, 2, 27, 37, 39, 42, 47, 55) . In humans, doses of 1,25(OH) 2D3 (0.5 g/kg or 38 g) furnished a similar clearance and exposure with minimal toxicity when used intermittently (8, 38) . Moreover, preliminary studies had shown that the chosen dosing regimen in mice elicited the desired pharmacological effect with only minor elevation of plasma calcium.
One mouse was euthanized at each blood sampling point for the treatment groups, and tissues were harvested at 0, 0.08, 0.25, 0.5, 1, 3, 6, 9, 12, 24, 48, 96, 192 , and 360 h after the first dose on day 0, and at 0, 0.5, 1, 3, 6, 9, 12, 24, and 48 h, after subsequent doses [in accordance with animal protocols approved by the University of Toronto (ON, Canada)]. For the control group (treated with corn oil only), however, sampling was conducted at 0, 3, 6, and 12 h on day 0, and at 0 h on days 2, 4, 6, 8 , and 14. The mouse was rendered unconscious in a carbon dioxide chamber before blood collection by cardiac puncture using a 1-ml syringe-23G 3/4 inch. needle set that was prerinsed with heparin (1,000 IU/ml). Plasma was obtained by centrifugation of blood at 3,000 rpm for 10 min. After flushing of ice-cold saline through the lower vena cava for the removal of blood, the kidneys were harvested, weighed, reduced to small pieces, snapfrozen in liquid nitrogen, and stored at Ϫ80°C for future analyses (11) . The small intestinal segments: the duodenum (spanning from the pyloric ring to the ligament of Treitz), proximal jejunum (6 cm after the ligament of Treitz), and ileum (6 cm proximal to the ileocecal junction) were removed as described (12) . After flushing of the segments with cold 1 mM phenylmethylsulfonyl fluoride (PMSF)-saline solution, the segments were everted and scraped, and the scrapings were snap-frozen in liquid nitrogen and stored at Ϫ80°C. The colon was also removed, flushed with cold 1 mM PMSF saline solution, blot-dried, snap-frozen in liquid nitrogen and stored at Ϫ80°C. For isolation of the femur (bone), the skin, muscle, tendon, and fat around the leg were removed and/or scraped off with a razor blade and then snap-frozen in liquid nitrogen and stored at Ϫ80°C until analyses.
Plasma calcium and phosphorus analyses and PTH assay. Calcium and phosphorus measurements in plasma were determined by inductively coupled plasma atomic emission spectroscopy (ICP-AES; Optima 3000 DV, PerkinElmer) as previously described (13) . Plasma was diluted 350-fold with 1% nitric acid before each measurement. Calcium was measured at 317.9 and 315.9 nm and phosphorus at 213.6 and 214.9 nm. PTH levels in 20 l of plasma were assayed by ELISA according to the manufacturer's protocol. (52) . Weighed kidney and scraped intestinal enterocyte samples were added to double-distilled water (wt/vol) to a final volume of 1 ml. The sample was homogenized with 3.75 ml of methylene chloride and methanol (1:2 vol/vol) using the Ultra-turrax T25 homogenizer (Janke & Kunkel, Staufen, Germany). The weighed femur was added to double distilled water (wt/vol up to 1 ml) and 3.75 ml of a mixture of methylene chloride and methanol (1:2 vol/vol) before the bone mixture was crushed using a mortar and pestle to obtain a homogenate. The final homogenate was mixed with 1.25 ml of methylene chloride and vortexed for 1 min, and then 1.25 ml double-distilled water was added and further mixed for another minute before centrifugation at 3,000 rpm for 20 min at room temperature. The methylene chloride (bottom phase) was collected using a glass pasteur pipette. Extraction of the homogenate was repeated upon addition of 1.25 ml of methylene chloride. The harvested methylene chloride extract was pooled, dried under nitrogen gas, and reconstituted with 0.3 ml of charcoal-stripped human serum (52) . The concentration of 1,25(OH)2D3 in mouse plasma or tissue was determined using the 1,25(OH)2D3 EIA kit following the manufacturer's protocol. Plasma and tissue samples, when out of the calibration range, were diluted with charcoal-stripped human serum before analysis. Delipidated solutions of tissue samples were spun at 12,000 g for 10 min through a 0.2 m Nanosep MF Centrifugal Device (Pall Life Sciences, Ville St. Laurent, QC) before addition for the immunocapsules for EIA.
Preparation of subcellular protein fractions of kidney and intestinal tissues. For preparation of the crude membrane fraction for the assay of Cyp24 or P-gp protein, kidney, colon tissue, or scraped enterocytes were homogenized in the crude membrane homogenizing buffer (250 mM sucrose, 10 mM HEPES, and 10 mM Trizma base, pH 7.4) containing 1% protease inhibitor cocktail (11) . This homogenate was used for Western blotting to measure total VDR protein expression. The homogenate was then centrifuged at 3,000 g for 10 min at 4°C, and the resulting pellet containing the mitochondrial fraction was resuspended in a buffer (in mM: 60 KCl, 15 NaCl, 5 MgCl2·6H2O, 0.1 EGTA, 300 sucrose, 0.5 DTT, 0.1 PMSF, 300 sucrose, and 15 Trizma HCl, pH 7.4) containing 1% protease inhibitor cocktail for Western blotting to measure Cyp24 protein expression. The supernatant was spun at 20,000 g for 60 min at 4°C, and the resulting pellet was resuspended in the resuspension buffer, as previ-ously described (12) , for Western blotting to measure P-gp and Trpv6 protein expression. Protein concentrations of the samples were assayed by the Lowry method (33), using bovine serum albumin as the standard. Samples were then stored at Ϫ80°C until Western blot analyses.
Western blotting. Total protein samples (15-50 g) were separated by 7.5-10% SDS-polyacrylamide gels at 100 V according to Chow et al. (11) . After separation and transfer of proteins onto a nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ), the membrane was blocked with 5% (wt/vol) skim milk in Tris-buffered saline (pH 7.4) and 0.1% Tween 20 (TBS-T; Sigma-Aldrich, Mississauga, ON, Canada) for 1 h at room temperature and then washed once with 0.1% TBS-T, followed by incubation with primary antibody solution in 2% skim milk in 0.1% TBS-T overnight at 4°C. On the next day, the membrane was washed with 0.1% TBS-T and then incubated with secondary antibody in 2% skim milk in 0.1% TBS-T for 2 h at room temperature and again washed with 0.1% TBS-T. Bands were visualized using chemiluminescence reagents (Amersham Biosciences) and quantified by scanning densitometry (NIH Image software; http:// rsb.info.nih.gov/nih-image/). Band intensity of the target protein was normalized to the protein band intensity of villin (95 kDa) for the intestinal samples and Gapdh (36 kDa) for the kidney samples. For comparison of intestinal and renal protein expression, both samples were normalized to that of Gadph.
Quantitative real-time PCR. Total RNA from kidney tissue and scraped intestinal enterocytes was extracted with the TRIzol extraction method (Sigma-Aldrich) according to the manufacturer's protocol, with modifications (11). About 1.5 g of cDNA was immediately synthesized from the RNA samples, using the High Capacity cDNA Reverse Transcription Kit (Life Technologies Canada, Burlington, ON, Canada), and qPCR was performed with the SYBR Green detection system as described (11) . Information on primer sequences is listed in Table 1 . All target mRNA data were normalized to cyclophillin mRNA for the kidney samples and villin mRNA for the intestinal samples, and the calculation of relative change in gene expression was performed as previously described (12) . 2 D 3 to mice. The baseline plasma concentration of 1,25(OH) 2 D 3 for vehicle-treated C57BL/6 mouse, estimated as the mean of the determinations for the experimental duration, was 212 Ϯ 29 pM (fmol/ml), a value similar to the endogenous plasma concentration of 1,25(OH) 2 D 3 in the rat (51) but higher than that in humans (8, 53) . Basal levels of 1,25(OH) 2 D 3 in the kidney (70.5 Ϯ 10.4 pmol/kg tissue), intestine (93.5 Ϯ 7.2 pmol/kg tissue), and bone (36.5 Ϯ 33.8 pmol/kg tissue) were significantly lower than those in plasma (Fig. 1A) ; the tissue/ plasma concentration ratios were 0.35, 0.4, and 0.17 for the kidney, ileum, and bone, respectively (Fig. 1B) . The less-thanunity tissue partitioning ratio may be explained by the high plasma binding of 1,25(OH) 2 D 3 relative to those in tissues.
RESULTS

Similar plasma and tissue (ileum, kidney, and bone) decay of 1,25(OH) 2 D 3 after single and multiple dosing of 1,25(OH)
After a single ip dose of 50 ng/mouse (120 pmol/mouse or 2.5 g/kg), 1,25(OH) 2 D 3 was rapidly absorbed (t max or time for maximum concentration of Յ0.5 h), yielding a peak plasma concentration (C max ) of 44 nM, followed by an apparent, biexponential decay profile ( Fig. 2A) with a half-life of ϳ6.86 h ( Table 2) . Distinctively, the plasma concentration of 1,25(OH) 2 D 3 fell below the baseline by the end of day 0, reached a nadir by day 4, and returned to baseline levels by day 8 ( Fig. 2A) . Subsequent to ip dosing of 1,25(OH) 2 D 3 , tissue levels in the kidney, ileum, and bone peaked at similar times [6, 4.5, and 0.065 nmol/kg (or pmol/g) tissue, respectively] and decayed in parallel fashion to that of plasma ( Fig. 2A) .
Following lower than that of the basal level, and the same pattern persisted throughout the dosing regimen. The renal, ileal, and bone 1,25(OH) 2 D 3 tissue concentrations rose in unison to those in plasma, reaching a peak concentration of 6.1, 1.8, 5.0, and 5.6 nmol/kg tissue in kidney, 4.5, 1.9, 1.9, and 2.8 nmol/kg tissue in ileum, and 0.065, 0.505, 7.65, and 1.8 nmol/kg tissue in bone, respectively, between 0.5 and 3 h after each of the four injections. These data confirm that 1,25(OH) 2 D 3 is able to equilibrate readily between plasma and tissue.
Multiple dosing of 1,25(OH) 2 D 3 resulted in a terminal or beta half-life of ϳ6.3 to 7.5 h (Fig. 2B) , and no trend was discernable upon repeated dosing (Table 2) . Overall, the decay pattern of 1,25(OH) 2 D 3 , based on the total 1,25(OH) 2 D 3 (exogenous ϩ basal) concentration after the administered 1,25(OH) 2 D 3 , and the exposure (AUC 0 -48 ) were similar after each injection (Fig. 2B, Table 2 ). There was little change in the pharmacokinetics of 1,25(OH) 2 D 3 upon repeated dosing, since change in the enzyme for catabolism, Cyp24a1, was maximal after a single dose (see results below for intestine and kidney). The half-life is similar to that observed from other ip studies in the mouse (7.6 h) (37) .
Intestinal distribution and effects of 1,25(OH) 2 D 3 on intestinal and colon VDR, Cyp24a1, and Trpv6 mRNA expression. The distribution of basal VDR mRNA expression was found to be higher for the duodenum than jejunum (50% of duodenum) and ileum (46% of duodenum) but was highest in the colon (1.5-fold of duodenum; Fig. 3A, left) . Basal Cyp24a1 mRNA expression was evenly distributed in the small intestine but was highest in colon (42-fold of duodenum; Fig. 3B, left) . The basal mRNA expression of Trpv6 was highest in the duodenum, followed by the colon (46% of duodenum), and was negligible in the jejunum and ileum (Ͻ1%; Fig. 3C, left) . At 3 h post-1,25(OH) 2 D 3 injection, there was no major change in VDR mRNA expression for all intestinal segments and the colon (Fig. 3A, left) . By contrast, Cyp24a1 and Trpv6 mRNA expressions were elevated Ͼ900-fold and Ͼ7-fold in the duodenal and ileal segments, respectively, although not for the jejunum due to sample variation (Figs. 3, B and C, left) . The lack of Cyp24a1 mRNA induction and small Trpv6 mRNA change in colon (Figs. 3, B (Fig. 3A, middle and right) , though the temporal ileal 1,25(OH) 2 D 3 concentrations rose in unison to that in plasma and remained mostly above basal levels during each injection interval (Fig. 2) . By contrast, ileal Cyp24a1 mRNA was induced significantly between 3 and 9 h after dosing (Fig. 3B, middle and right) , with patterns similar to the temporal changes of 1,25(OH) 2 D 3 in ileum (Fig. 2) . The induction of Cyp24a1 mRNA was dramatically increased (Ͼ500-fold) after the first dose (Fig. 3B, middle) , but the inductions were slightly lessened (300-to 400-fold) for the 2nd, 3rd, and 4th doses, with mRNA levels rapidly returning to baseline at 24 h after dosing (Fig. 3B, right) . A single administration of 1,25(OH) 2 D 3 resulted in a 30-fold maximal increase in ileal Trpv6 mRNA at 9 h (Fig. 3C, middle) . However, multiple dosing of 1,25(OH) 2 D 3 greatly magnified the increase of ileal Trpv6 to 200-to 600-fold, with higher changes observed at the 3rd and 4th doses (Fig. 3C, middle and right) .
Induction of renal VDR, Cyp24a1, and Trpv6 and downregulation of Cyp27b1 mRNA were time and concentration dependent. Unlike the modest change of VDR mRNA observed for the intestine, renal VDR mRNA rose 2-fold between 3 and 12 h after the single 1,25(OH) 2 D 3 dose, and this increase was sustained for the entire week before levels returned to baseline. With multiple dosing, renal VDR mRNA levels for subsequent doses were further increased to 2.5-then 4-fold higher over basal levels (Fig. 4A) . After a single 1,25(OH) 2 D 3 dose, renal Cyp24a1 mRNA expression was increased 77-fold and peaked at ϳ9 h, and levels remained high and above baseline for 8 days, whereas multiple dosing of 1,25(OH) 2 D 3 induced and maintained Cyp24a1 mRNA over 40-fold above basal levels (Fig. 4B) . Injection of a single 1,25(OH) 2 D 3 dose resulted in a 5-fold maximal increase in renal Trpv6 mRNA at 9 h, whereas multiple dosing greatly magnified the increase of renal Trpv6, with higher changes observed for Trpv6 mRNA at the 3rd and 4th doses of ϳ10-to 12-fold above basal levels (Fig. 4C) . For renal Cyp27b1 mRNA, there was an immediate rise above basal level at 0.5 h following the first injection, but this change was followed by a rapid decrease to 34% of basal level at 3 h (Fig. 4D) ; these levels were maintained below basal levels (8 -30%) before returning back to baseline on the 8th day, and the average renal Cyp27b1 mRNA level was ϳ3-30% of basal levels during repetitive dosing (Fig. 4D) 2 D 3 . Similarly, renal Mdr1 mRNA showed a relatively small increase (1.5-to 2-fold) before returning back to basal level 6 h after the single administration (Fig. 5A) . However, upon repetitive dosing, a disproportionate and sustained increase (Ͼ10-fold) was observed (Fig. 5B) . Renal P-gp protein levels resulting from 1,25(OH) 2 D 3 repetitive treatment rose on average 5-fold above basal levels (Fig. 5C) .
Temporal changes in intestinal and renal VDR, Cyp24, and Trpv6 protein expression vs. plasma calcium and PTH levels in single and multiple doses of 1,25(OH) 2 D 3 in mice.
Basal protein level of VDR was higher in the duodenum than in ileum (30% of duodenum) but was highest in colon (4-fold; Fig. 6A ), whereas VDR protein was similar between the duodenum and kidney (Fig. 6B) . Changes in protein expression of VDR were different compared with its mRNA expression (Fig.  3A) . When examined, VDR protein in the various segments showed differential temporal changes with 1,25(OH) 2 D 3 treatment for the duodenum, ileum, and colon. VDR protein in duodenum was elevated after the 2nd and 3rd 1,25(OH) 2 D 3 injections, whereas VDR protein level in the colon was increased after the 3rd and 4th injections (Fig. 6C ). There were higher protein changes but a lack of change in ileal VDR mRNA with treatment (Fig. 3A) , and this could be explained by the action of 1,25(OH) 2 D 3 in increasing the half-life of VDR protein (31) . Renal VDR protein, similar to VDR mRNA, rose rapidly after the 1st dose, and was sustained for the 2nd and 4th doses (Fig. 6C) . Furthermore, multiple administration of 1,25(OH) 2 D 3 increased Cyp24 protein in ileum steadily at 1.5-fold above basal level (Fig. 7A) , whereas the changes for renal Cyp24 protein were considerably higher (10-fold on average) than in ileum (Fig. 7B) .
We then examined basal levels of Trvp6 protein in the duodenum, ileum, and colon and found the rank order of duodenum Ͼ colon (72% of duodenum) Ͼ ileum (25% of duodenum) (Fig. 8A) . The basal level of Trpv6 protein of the kidney was only 43% of that in duodenum (Fig. 8B) . With 1,25(OH) 2 D 3 treatment, Trpv6 protein levels were increased 1.5-fold on average throughout the treatment period for the duodenum and ileum after the 3rd and 4th doses, whereas levels in the colon were increased after the 4th dose (Fig. 8C) . These changes in protein are consistent with a high Trpv6 mRNA induction in ileum at the same period (Fig. 3C) . Furthermore, levels of plasma calcium were correlated to changes in Trpv6 mRNA (Fig. 3C) and protein (Fig. 8C) . There was virtually no discernable change in calcium levels after a single dose, whereas cumulative changes were observed after the 2nd to 4th doses (Fig. 8D) . These changes could be attributed to the relatively high and transient elevation of both the intestinal and renal Trpv6 mRNA, raising the plasma calcium concentrations by 10 -40% during the successive dosing regimen (Fig. 8D) . However, due to the 2.2-fold higher Trpv6 protein level in the duodenum compared with that in kidney (Fig. 8B) , the intestine is likely a greater contributor to calcium absorption. This notion was supported by others as well (15, 54) . The mean basal plasma PTH level was ϳ68.8 Ϯ 14.8 pg/ml in control mice (Fig. 9) . After a single dose of 1,25(OH) 2 D 3 , mouse plasma PTH initially increased (to ϳ148 pg/ml) in the first 5 min postinjection, but levels then immediately dropped to 12-34 pg/ml between 6 and 48 h before returning back to basal levels on the eighth day (Fig. 9A) . Multiple dosing of 1,25(OH) 2 D 3 to mice generally led to sustained decreased plasma PTH (between 0 and 30 pg/ml) throughout the course of treatment, except at two sampling time points (0.5 h after 3rd injection and 9 h after 4th injection; Fig. 9B ), likely due to sampling variation and small sample size.
DISCUSSION
Our efforts represent one of the first studies to examine plasma and tissue 1,25(OH) 2 D 3 concentrations accompanying the exogenous 1,25(OH) 2 D 3 administration to mice. Despite being tightly bound to the vitamin D binding protein (DBP) in the plasma, we observed rapid distribution of 1,25(OH) 2 D 3 into tissues due to the lipophilic nature of the compound (19) . 1,25(OH) 2 D 3 is able to enter and distribute into tissues rapidly, including the kidney, intestine, bone (Fig. 1) , liver, and brain (data not shown) regardless of differences in VDR abundance. The parallel patterns of rise and decay for 1,25(OH) 2 D 3 sug- gest rapid entry, distribution, and equilibrium between tissue and plasma. 1,25(OH) 2 D 3 concentrations in the kidney and intestine remained predominantly above basal levels during and after 1,25(OH) 2 D 3 treatment (Fig. 2) , implying that the present regimen for treatment of 1,25(OH) 2 D 3 could result in sustained local pharmacological effects. Under basal conditions, the tissue-to-plasma partitioning ratios are for ileum 0.41 Ϯ 0.12, for kidney 0.33 Ϯ 0.07, and for bone 0.15 Ϯ 0.16 ( Fig. 1) . Those in the liver (0.13 Ϯ 0.04) and brain (0.007 Ϯ 0.003) were also lower (data not shown). Upon correlation of the plasma and tissue 1,25(OH) 2 D 3 concentration-time profiles to changes of VDR target genes in mice, we found that maximal induction of VDR target genes such as Trpv6 and Cyp24a1 mRNA expression in intestine were similar after single vs. repeated dosing (Figs. 3, B and C) , with the peak occurring between 3 and 9 h postinjection, lagging behind the peak 1,25(OH) 2 D 3 concentration in ileum (at ϳ0.5-1 h) (Fig. 2) . This lag time is not unexpected and is likely the result of the time required for translocation of the VDR into the nucleus for heterodimerization with the RXR to initiate transcription. Changes in renal VDR, Cyp24, and Mdr1 mRNA expression also showed the time lag but were more sustained after repeated dosing, since the VDR level was elevated and was more responsive to 1,25(OH) 2 D 3 treatment (Figs. 4 and 5 ). In addition, tissue ileal and kidney concentrations of 1,25(OH) 2 D 3 at 3-9 h after each 1,25(OH) 2 D 3 administration remained elevated above baseline values (Fig. 2) , at which time maximal induction of renal and ileal Cyp24a1, VDR and Trpv6 mRNA expression was noted (Figs. 3 and 4) .
Cyp24a1 is a major VDR-responsive gene (9, 29) (30) , and absence of Cyp24a1 in Cyp24 knockout mice drastically reduces 1,25(OH) 2 D 3 metabolism (35) . In this study, we found that induction of ileal Cyp24a1 mRNA (Fig. 3B ) was much greater than that for renal Cyp24a1 (Fig. 4B) , although renal Cyp24a1 induction was more sustained (maintained above 40-fold of basal level) than that of the ileum, whose Cyp24a1 levels rapidly returned to basal levels at 24 h (Fig. 3B) . There are perhaps two potential explanations. First, enterocytes in the intestine have a much higher turnover rate than renal tubular cells (7, 24) , reducing the sustainability of ileal Cyp24a1 induction. Second, renal and not ileal VDR was induced, and renal induction of VDR continued upon multiple dosing of 1,25(OH) 2 D 3 (Fig. 4B) , resulting in higher expression of renal Cyp24a1 mRNA. Visually, a correlation could be identified between renal VDR and Cyp24a1 mRNA levels (Fig. 4B) , although no correlation was noted between ileal Cyp24a1 mRNA and VDR due to the small change in VDR (Fig. 3B) .
The induction pattern of renal Mdr1 mRNA (Fig. 5B ), another VDR target gene (44) , was similar to that of renal VDR mRNA (Fig. 4A) . Induction of both Mdr1 mRNA and P-gp protein was sustained in the kidney after consecutive injections of 1,25(OH) 2 D 3 (Fig. 5, B and C) . A higher P-gp protein expression (2.7-fold increase) was observed previously for the enhanced renal but not intestinal excretion of digoxin, a P-gp substrate, when the same 1,25(OH) 2 D 3 doses were administered to the mouse (11), as found in the present study (Fig. 5C) . Thus, VDR regulates Mdr1 and P-gp induction in a tissuespecific manner.
Plasma calcium levels (Fig. 8D) were greatly influenced by temporal changes in mRNA and protein expression of Trpv6, which was increased by 1,25(OH) 2 D 3 treatment in both the intestine and kidney (Figs. 3C, 4C, and 8C) . The calcium channel Trpv6 together with Trpv5 mediate the transcellular calcium transport following binding to calbindin to facilitate calcium diffusion across the basolateral membrane and extrusion via the ATP-dependent Ca 2ϩ -ATPase, PMCA1b, and Na ϩ /Ca 2ϩ exchanger NCX1 (28). Trpv6 is a major contributor for the apical, intestinal absorption of calcium, since a lack of Trpv6 in knockout mice resulted in significant reduction in calcium absorption and plasma calcium levels (5, 16) . Calcium balance is intimately related to Trpv5/6, whose channel activities are stimulated by the VDR primarily via the genomic transcription of the VDREs and by the estrogen receptor, ER␣ (28) . The increase in Trpv6 mRNA and protein expression in the mouse intestine and kidney strongly correlates with the increase (10 -40%) in plasma calcium (Figs. 3C, 4C, and D) that in turn attenuated plasma PTH level (Fig. 9B) under our dosing regimen of 1,25(OH) 2 D 3 . Elevated plasma calcium is expected to activate the CaSR in the parathyroid gland to inhibit synthesis of PTH, which in turn reduces the mRNA expression of renal Cyp27b1 (23, 30) . These immediate changes were found in response to the single and multiple 1,25(OH) 2 D 3 doses in our study (Fig. 4D) . Changes in ileal and renal Trpv6 protein expression and calcium (Fig. 8, C  and D) indirectly regulated renal Cyp27b1 (Fig. 4D) via reduction of PTH (Fig. 9) . Moreover, the higher Trpv6 protein content in the duodenum compared with that in kidney (Fig. 8B) suggests that the intestine is the more important organ than the kidney with respect to Trpv6 induction and calcium absorption (Fig. 8D) .
Treatment of 1,25(OH) 2 D 3 is known to result in both genomic and nongenomic effects (43) , as noted for Cyp24 (25, 40) . However, nongenomic effects are difficult to monitor, since these effects occur rapidly (from seconds to a few minutes), exemplified by the opening of calcium channels for calcium influx without changes in gene or protein (43) . We believe that chronic treatment of 1,25(OH) 2 D 3 will result in VDR effects that are mostly genomic, since there are notable changes in mRNA and protein levels of VDR target genes, namely, VDR, Cyp24a1, Trpv6, and Mdr1/P-gp (Figs. 3-8 ).
Then we examined the correlation between 1,25(OH) 2 D 3 levels vs. mRNA expression of VDR target genes. Our data revealed that the concentrations of 1,25(OH) 2 D 3 in plasma and tissues peaked at 0.5 to 1 h (Fig. 2 ) and decayed rapidly with a t 1/2 of ϳ6 h (Table 2) , and induction of mRNA expression of VDR target genes in the ileum and kidney peaked at 3-9 h (Figs. 3  and 4 ), but there was no distinct pattern for protein expressions for many of the VDR target genes (Figs. 6 -8 ). In sum, the derived correlation was not always meaningful. A positive correlation would have been expected between the 1,25(OH) 2 D 3 and calcium levels in plasma if nongenomic effects had prevailed; however, a negative correlation was observed (data not shown). As expected, the correlation failed to divulge information on VDR mechanisms. The transduction processes are a multistep phenomenon that may involve multiple organs and multiple feedback or feed-forward loops, which is quite complex, especially with respect to calcium elevation.
Data from this study conclusively show that 1,25(OH) 2 D 3 enters tissues rapidly, shown by the parallel disposition profiles. The terminal half-life and the area under the curve (AUC 0 -48 ) of total 1,25(OH) 2 D 3 (administered ϩ endogenous) remained relatively unchanged between doses, and no trend was identifiable (Table 2 and Fig. 2 ). The lack of pharmacokinetic changes in drug exposure in these mouse studies is attributed to the immediate, maximal changes in the degradation and synthetic enzymes, Cyp24a1 and Cyp27b1, by VDR activation after the first administration of 1,25(OH) 2 D 3 . Hence, repeated dosing renders similar pharmacokinetic effects. A pattern may be discerned for the temporal changes in tissue where concentrations of 1,25(OH) 2 D 3 are correlated to temporal changes in the expression of some VDR target genes. VDR activation increased Trpv6 expression, which was higher in intestine and less so in kidney. Trpv6 is also responsible for the sustained elevation of calcium and attenuation of PTH in plasma upon repeated 1,25(OH) 2 
